Notice: Get a jump on 2015 — Pay your 2015 ASA membership dues now!




January 23 - 25 2015, 12:00 AM - 12:00 AM


February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

June 26 - 28 2015, 12:00 AM - 12:00 AM

Annual Perioperative Surgical Home Summit



December 18, 2014

0.9 Percent Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container by Baxter: Recall - Particulate Matter


FDA MedWatch Recall - Particulate Matter

November 21, 2014

FDA MedWatch - Respironics California, Esprit V1000 and V200 Ventilators: Class I Recall - Power Failure May Occur


FDA MedWatch Respironics California Esprit V1000 and V200 Ventilators Class I Recall

November 21, 2014

FDA MedWatch - Highly Concentrated Potassium Chloride Injection, 10 mEq per 100 mL by Baxter: Recall - Mislabeled


Highly Concentrated Potassium Chloride Injection 10 mEq per 100 mL by Baxter Recall Mislabeled



Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

Appeals Court Rules Against FDA in Sodium Thiopental Importation Case

Monday, July 29, 2013

On July 23, the United States Court of Appeals for the District of Columbia Circuit ruled in Cook v. Food and Drug Administration (FDA) that the FDA cannot permit importation of sodium thiopental into the United States because it is a misbranded and unapproved drug. 

Several prisoners on death row sued the FDA over the decision to permit state departments of correction to import sodium thiopental from overseas companies that are not registered with the FDA.  Sodium thiopental is used in lethal injection protocols.

According to the court's opinion, the FDA argued that "it must have discretion not to enforce § 381(a) in order to combat domestic shortages of medically necessary drugs."  The court disagreed and noted that the FDA has methods other than importation to counteract a drug shortage, such as working with manufacturers to increase production or mitigate quality problems. 

Public reports indicate the FDA is currently reviewing the court’s decision.  

ASA is also reviewing the opinion.

Review the opinion.

« Back to Washington Alerts